Report Detail
Global IBS Treatment Market Professional Survey Report 2019
- RnM3720876 |
- 03 September, 2019 |
- Global |
- 125 Pages |
- QYResearch |
- Pharma & Healthcare
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
The global IBS Treatment market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on IBS Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall IBS Treatment market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of IBS Treatment in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their IBS Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Allergan Plc (Ireland)
Sucampo Pharmaceuticals (US)
Ironwood Pharmaceuticals, Inc. (US)
Astellas Pharma Inc. (Japan)
Valeant Pharmaceuticals (Canada)
Abbott Laboratories (US)
Synergy Pharmaceuticals, Inc. (US)
Ardelyx, Inc. (US)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA, Inc. (Italy)
RedHill Biopharma Ltd. (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Ltd (Japan)
Synthetic Biologics, Inc. (US)
Protagonist Therapeutics Inc. (US)
Pfizer Inc (US)
Lexicon Pharmaceuticals, Inc. (US)
Innovate Biopharmaceuticals (US)
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
By Types
IBS-D
IBS-C
IBS-M
By Drugs Type
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
Segment by Application
Hospitals
Clinics
Research Laboratories
Table of Contents
Executive Summary
1 Industry Overview of IBS Treatment
- 1.1 Definition of IBS Treatment
- 1.2 IBS Treatment Segment By Types
- 1.2.1 Global IBS Treatment Production Growth Rate Comparison By Types (2014-2025)
- 1.2.2 IBS-D
- 1.2.3 IBS-C
- 1.2.4 IBS-M
- 1.3 IBS Treatment Segment by Applications
- 1.3.1 Global IBS Treatment Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Research Laboratories
- 1.4 Global IBS Treatment Overall Market
- 1.4.1 Global IBS Treatment Revenue (2014-2025)
- 1.4.2 Global IBS Treatment Production (2014-2025)
- 1.4.3 North America IBS Treatment Status and Prospect (2014-2025)
- 1.4.4 Europe IBS Treatment Status and Prospect (2014-2025)
- 1.4.5 China IBS Treatment Status and Prospect (2014-2025)
- 1.4.6 Japan IBS Treatment Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia IBS Treatment Status and Prospect (2014-2025)
- 1.4.8 India IBS Treatment Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of IBS Treatment
- 2.3 Manufacturing Process Analysis of IBS Treatment
- 2.4 Industry Chain Structure of IBS Treatment
3 Development and Manufacturing Plants Analysis of IBS Treatment
- 3.1 Capacity and Commercial Production Date
- 3.2 Global IBS Treatment Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of IBS Treatment
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 IBS Treatment Production and Capacity Analysis
- 4.2 IBS Treatment Revenue Analysis
- 4.3 IBS Treatment Price Analysis
- 4.4 Market Concentration Degree
5 IBS Treatment Regional Market Analysis
- 5.1 IBS Treatment Production by Regions
- 5.1.1 Global IBS Treatment Production by Regions
- 5.1.2 Global IBS Treatment Revenue by Regions
- 5.2 IBS Treatment Consumption by Regions
- 5.3 North America IBS Treatment Market Analysis
- 5.3.1 North America IBS Treatment Production
- 5.3.2 North America IBS Treatment Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America IBS Treatment Import and Export
- 5.4 Europe IBS Treatment Market Analysis
- 5.4.1 Europe IBS Treatment Production
- 5.4.2 Europe IBS Treatment Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe IBS Treatment Import and Export
- 5.5 China IBS Treatment Market Analysis
- 5.5.1 China IBS Treatment Production
- 5.5.2 China IBS Treatment Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China IBS Treatment Import and Export
- 5.6 Japan IBS Treatment Market Analysis
- 5.6.1 Japan IBS Treatment Production
- 5.6.2 Japan IBS Treatment Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan IBS Treatment Import and Export
- 5.7 Southeast Asia IBS Treatment Market Analysis
- 5.7.1 Southeast Asia IBS Treatment Production
- 5.7.2 Southeast Asia IBS Treatment Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia IBS Treatment Import and Export
- 5.8 India IBS Treatment Market Analysis
- 5.8.1 India IBS Treatment Production
- 5.8.2 India IBS Treatment Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India IBS Treatment Import and Export
6 IBS Treatment Segment Market Analysis (by Type)
- 6.1 Global IBS Treatment Production by Type
- 6.2 Global IBS Treatment Revenue by Type
- 6.3 IBS Treatment Price by Type
7 IBS Treatment Segment Market Analysis (by Application)
- 7.1 Global IBS Treatment Consumption by Application
- 7.2 Global IBS Treatment Consumption Market Share by Application (2014-2019)
8 IBS Treatment Major Manufacturers Analysis
- 8.1 Allergan Plc (Ireland)
- 8.1.1 Allergan Plc (Ireland) IBS Treatment Production Sites and Area Served
- 8.1.2 Allergan Plc (Ireland) Product Introduction, Application and Specification
- 8.1.3 Allergan Plc (Ireland) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Sucampo Pharmaceuticals (US)
- 8.2.1 Sucampo Pharmaceuticals (US) IBS Treatment Production Sites and Area Served
- 8.2.2 Sucampo Pharmaceuticals (US) Product Introduction, Application and Specification
- 8.2.3 Sucampo Pharmaceuticals (US) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Ironwood Pharmaceuticals, Inc. (US)
- 8.3.1 Ironwood Pharmaceuticals, Inc. (US) IBS Treatment Production Sites and Area Served
- 8.3.2 Ironwood Pharmaceuticals, Inc. (US) Product Introduction, Application and Specification
- 8.3.3 Ironwood Pharmaceuticals, Inc. (US) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Astellas Pharma Inc. (Japan)
- 8.4.1 Astellas Pharma Inc. (Japan) IBS Treatment Production Sites and Area Served
- 8.4.2 Astellas Pharma Inc. (Japan) Product Introduction, Application and Specification
- 8.4.3 Astellas Pharma Inc. (Japan) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Valeant Pharmaceuticals (Canada)
- 8.5.1 Valeant Pharmaceuticals (Canada) IBS Treatment Production Sites and Area Served
- 8.5.2 Valeant Pharmaceuticals (Canada) Product Introduction, Application and Specification
- 8.5.3 Valeant Pharmaceuticals (Canada) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 Abbott Laboratories (US)
- 8.6.1 Abbott Laboratories (US) IBS Treatment Production Sites and Area Served
- 8.6.2 Abbott Laboratories (US) Product Introduction, Application and Specification
- 8.6.3 Abbott Laboratories (US) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 Synergy Pharmaceuticals, Inc. (US)
- 8.7.1 Synergy Pharmaceuticals, Inc. (US) IBS Treatment Production Sites and Area Served
- 8.7.2 Synergy Pharmaceuticals, Inc. (US) Product Introduction, Application and Specification
- 8.7.3 Synergy Pharmaceuticals, Inc. (US) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 Ardelyx, Inc. (US)
- 8.8.1 Ardelyx, Inc. (US) IBS Treatment Production Sites and Area Served
- 8.8.2 Ardelyx, Inc. (US) Product Introduction, Application and Specification
- 8.8.3 Ardelyx, Inc. (US) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 Nestle (Switzerland)
- 8.9.1 Nestle (Switzerland) IBS Treatment Production Sites and Area Served
- 8.9.2 Nestle (Switzerland) Product Introduction, Application and Specification
- 8.9.3 Nestle (Switzerland) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 Sebela Pharmaceuticals (Ireland)
- 8.10.1 Sebela Pharmaceuticals (Ireland) IBS Treatment Production Sites and Area Served
- 8.10.2 Sebela Pharmaceuticals (Ireland) Product Introduction, Application and Specification
- 8.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
- 8.11 Probi (Sweden)
- 8.12 Alfasigma USA, Inc. (Italy)
- 8.13 RedHill Biopharma Ltd. (Israel)
- 8.14 AstraZeneca (U.K)
- 8.15 Ipsen (France)
- 8.16 Novartis AG (Switzerland)
- 8.17 Takeda Pharmaceutical Company Ltd (Japan)
- 8.18 Synthetic Biologics, Inc. (US)
- 8.19 Protagonist Therapeutics Inc. (US)
- 8.20 Pfizer Inc (US)
- 8.21 Lexicon Pharmaceuticals, Inc. (US)
- 8.22 Innovate Biopharmaceuticals (US)
9 Development Trend of Analysis of IBS Treatment Market
- 9.1 Global IBS Treatment Market Trend Analysis
- 9.1.1 Global IBS Treatment Market Size (Volume and Value) Forecast 2019-2025
- 9.2 IBS Treatment Regional Market Trend
- 9.2.1 North America IBS Treatment Forecast 2019-2025
- 9.2.2 Europe IBS Treatment Forecast 2019-2025
- 9.2.3 China IBS Treatment Forecast 2019-2025
- 9.2.4 Japan IBS Treatment Forecast 2019-2025
- 9.2.5 Southeast Asia IBS Treatment Forecast 2019-2025
- 9.2.6 India IBS Treatment Forecast 2019-2025
- 9.3 IBS Treatment Market Trend (Product Type)
- 9.4 IBS Treatment Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 IBS Treatment Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on IBS Treatment. Industry analysis & Market Report on IBS Treatment is a syndicated market report, published as Global IBS Treatment Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of IBS Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
